Roche Diagnostics announced today it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous ...

The investment will make the Indianapolis facility the hub for manufacturing of Roche’s continuous glucose monitoring system.

The investment, which is expected to be complete by 2030, will boost U.S. production of Roche’s continuous glucose monitoring ...

Roche announced today that it plans to invest up to $550 million to expand its continuous glucose monitoring (CGM) site in ...

Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its ...

The move is part of Roche’s previously announced plan to invest $50 billion in pharmaceuticals and diagnostics over the next ...

Roche plans to invest as much as $550 million in its Indianapolis diagnostics campus during the next five years, with plans to build it into a U.S. | The announcement follows a five-year, $50 billion ...

The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) system. The ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert on the circulation of ...

Officials with Roche Diagnostics announced on Monday that it will invest $550 million in its Indianapolis site by 2030.

INDIANAPOLIS — Roche has announced plans to invest up to $550 million in its Diagnostics facility in Indianapolis by 2030.

The facility produces about 5.2 billion Accu-Chek diabetes test strips annually and serves as one of the company’s two global distribution hubs focused on serving the U.S. market and supporting ...